| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Marc Humbert | Q33113039 |
| Peter Dorfmuller | Q37842237 | ||
| Karl Balabanian | Q47976012 | ||
| Frédéric Perros | Q56606126 | ||
| P2093 | author name string | M Humbert | |
| F Perros | |||
| K Balabanian | |||
| P Dorfmüller | |||
| P433 | issue | 2 | |
| P921 | main subject | inflammation | Q101991 |
| P304 | page(s) | 358-363 | |
| P577 | publication date | 2003-08-01 | |
| P1433 | published in | European Respiratory Journal | Q12257435 |
| P1476 | title | Inflammation in pulmonary arterial hypertension | |
| P478 | volume | 22 |
| Q27026643 | A comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet? |
| Q37359026 | A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension |
| Q34315713 | AAV delivery of tumor necrosis factor-α short hairpin RNA attenuates cold-induced pulmonary hypertension and pulmonary arterial remodeling |
| Q36330527 | Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling |
| Q38876540 | Acquired Mitochondrial Abnormalities, Including Epigenetic Inhibition of Superoxide Dismutase 2, in Pulmonary Hypertension and Cancer: Therapeutic Implications |
| Q43181950 | Acute pulmonary arterial hypertension associated with anti-synthetase syndrome |
| Q43117862 | Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension |
| Q37337539 | Adiponectin deficiency: a model of pulmonary hypertension associated with pulmonary vascular disease. |
| Q30620974 | Adventitial alterations are the main features in pulmonary artery remodeling due to long-term chronic intermittent hypobaric hypoxia in rats |
| Q92263764 | Adverse effects of BMPR2 suppression in macrophages in animal models of pulmonary hypertension |
| Q43270607 | Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension |
| Q36725312 | An inhibitory effect of tumor necrosis factor-alpha antagonist to gene expression in monocrotaline-induced pulmonary hypertensive rats model |
| Q83454280 | Antagonism of CXCR7 attenuates chronic hypoxia-induced pulmonary hypertension |
| Q39405856 | Anti-endothelial cell antibodies in connective tissue diseases associated with pulmonary arterial hypertension |
| Q35537991 | Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension |
| Q90413044 | Association between cytokines and functional, hemodynamic parameters, and clinical outcomes in pulmonary arterial hypertension |
| Q34235628 | Asthma and pulmonary arterial hypertension: do they share a key mechanism of pathogenesis? |
| Q50994238 | Astragalus Polysaccharides Attenuate Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats |
| Q35142695 | BMP pathway regulation of and by macrophages |
| Q42570141 | BMP type II receptor deficiency confers resistance to growth inhibition by TGF-β in pulmonary artery smooth muscle cells: role of proinflammatory cytokines |
| Q33849207 | Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies |
| Q88673258 | Beneficial effects of fenofibrate in pulmonary hypertension in rats |
| Q33593640 | Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension |
| Q37530800 | CD4+ T cells and IFN-γ are required for the development of Pneumocystis-associated pulmonary hypertension |
| Q36628843 | CXCL13 in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension |
| Q33160867 | Cardiac-specific genetic inhibition of nuclear factor-κB prevents right ventricular hypertrophy induced by monocrotaline |
| Q46548988 | Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat. |
| Q35929761 | Characterization of altered patterns of endothelial progenitor cells in sickle cell disease related pulmonary arterial hypertension |
| Q44490545 | Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus |
| Q51743683 | Chronic intermittent hypobaric hypoxia attenuates monocrotaline-induced pulmonary arterial hypertension via modulating inflammation and suppressing NF-κB/p38 pathway. |
| Q36482251 | Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension |
| Q41528822 | Circulating microparticles in severe pulmonary arterial hypertension increase intercellular adhesion molecule-1 expression selectively in pulmonary artery endothelium |
| Q60363740 | Classical IL-6 signaling: a promising therapeutic target for pulmonary arterial hypertension |
| Q42573967 | Contributions of pulmonary hypertension to HIV-related cardiac dysfunction |
| Q27005594 | DNA Damage and Pulmonary Hypertension |
| Q45904145 | Delta chemokine (fractalkine) – A novel mediator of pulmonary arterial hypertension in children undergoing cardiac surgery |
| Q83694471 | Dexamethasone attenuates development of monocrotaline-induced pulmonary arterial hypertension |
| Q58087645 | Diaphragm Muscle Fiber Weakness in Pulmonary Hypertension |
| Q37070077 | Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. |
| Q37677437 | Discerning functional hierarchies of microRNAs in pulmonary hypertension |
| Q46578580 | Docosapentaenoic acid monoacylglyceride reduces inflammation and vascular remodeling in experimental pulmonary hypertension |
| Q41034799 | Dysregulation of microRNA-214 and PTEN contributes to the pathogenesis of hypoxic pulmonary hypertension |
| Q54425463 | Dysregulation of the IL-13 receptor system: a novel pathomechanism in pulmonary arterial hypertension. |
| Q46835493 | Effect of thrombomodulin on the development of monocrotaline-induced pulmonary hypertension. |
| Q33738592 | Effects of exercise training on pulmonary hemodynamics, functional capacity and inflammation in pulmonary hypertension |
| Q35175427 | Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension |
| Q33799629 | Endothelial Krüppel-like factor 4 modulates pulmonary arterial hypertension |
| Q37209074 | Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension. |
| Q36120117 | Estrogen paradox in pulmonary hypertension: current controversies and future perspectives |
| Q35527919 | Estrogen rescues preexisting severe pulmonary hypertension in rats |
| Q34284458 | Exercise intolerance in pulmonary arterial hypertension |
| Q33859158 | Fluoxetine inhibited extracellular matrix of pulmonary artery and inflammation of lungs in monocrotaline-treated rats |
| Q90379507 | Formulation and Characterization of Solid Lipid Nanoparticles Loading RF22-c, a Potent and Selective 5-LO Inhibitor, in a Monocrotaline-Induced Model of Pulmonary Hypertension |
| Q43538214 | Functional implications of IgG anti-endothelial cell antibodies in pulmonary arterial hypertension |
| Q36752306 | Genetics and mediators in pulmonary arterial hypertension |
| Q54595527 | Guest editorial--novel insights into the pathology of Stachybotrys chartarum. |
| Q35208059 | HMGB1 promotes the development of pulmonary arterial hypertension in rats |
| Q61895132 | HTAP des connectivites |
| Q34958933 | Heterozygous null bone morphogenetic protein receptor type 2 mutations promote SRC kinase-dependent caveolar trafficking defects and endothelial dysfunction in pulmonary arterial hypertension |
| Q36977316 | High levels of hyaluronan in idiopathic pulmonary arterial hypertension |
| Q36619246 | High levels of zinc-protoporphyrin identify iron metabolic abnormalities in pulmonary arterial hypertension |
| Q54737397 | Hospital and intensive care unit management of decompensated pulmonary hypertension and right ventricular failure. |
| Q36216790 | Human VIP-alpha: an emerging biologic response modifier to treat primary pulmonary hypertension |
| Q46280825 | Hypoxia and Local Inflammation in Pulmonary Artery Structure and Function |
| Q33703652 | Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells |
| Q36009074 | Hypoxia, leukocytes, and the pulmonary circulation |
| Q37162764 | Hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELMalpha) induces the vascular and hemodynamic changes of pulmonary hypertension |
| Q36541868 | Hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELMα) in chronic hypoxia- and antigen-mediated pulmonary vascular remodeling |
| Q35087969 | Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage |
| Q34914125 | IL-1β and IL-18: inflammatory markers or mediators of hypertension? |
| Q36341659 | Identification of Biomarkers for Schistosoma-Associated Pulmonary Arterial Hypertension Based on RNA-Seq Data of Mouse Whole Lung Tissues |
| Q34913082 | Idiopathic pulmonary arterial hypertension: an avian model for plexogenic arteriopathy and serotonergic vasoconstriction |
| Q47742357 | Immune cells and autoantibodies in pulmonary arterial hypertension |
| Q42273111 | Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice |
| Q84435696 | Impairment of monocyte-derived dendritic cells in idiopathic pulmonary arterial hypertension |
| Q34109306 | Increased levels of asymmetric dimethylarginine are associated with pulmonary arterial hypertension in HIV infection |
| Q35289907 | Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension. |
| Q34536425 | Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension |
| Q34649842 | Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice |
| Q34101823 | Indispensable roles of OX40L-derived signal and epistatic genetic effect in immune-mediated pathogenesis of spontaneous pulmonary hypertension |
| Q33898213 | Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension |
| Q52720539 | Inflammatory Macrophage Expansion in Pulmonary Hypertension Depends upon Mobilization of Blood-Borne Monocytes. |
| Q54595523 | Inhalation of Stachybotrys chartarum evokes pulmonary arterial remodeling in mice, attenuated by Rho-kinase inhibitor. |
| Q64137186 | Inhibition of CRTH2-mediated Th2 activation attenuates pulmonary hypertension in mice |
| Q33824233 | Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats |
| Q92545496 | Inhibitory effects of formononetin on the monocrotaline‑induced pulmonary arterial hypertension in rats |
| Q43227366 | Innate immunity in the therapeutic actions of endothelial progenitor cells in pulmonary hypertension |
| Q35565086 | Interleukin-6 and tumor necrosis factor-α are associated with quality of life-related symptoms in pulmonary arterial hypertension |
| Q35644609 | Interleukin-6/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension |
| Q42139850 | Intralipid prevents and rescues fatal pulmonary arterial hypertension and right ventricular failure in rats |
| Q91649600 | Involvement of immune responses in pulmonary arterial hypertension; lessons from rodent models |
| Q43458362 | Iptakalim ameliorates monocrotaline-induced pulmonary arterial hypertension in rats |
| Q37787547 | Key role of the RhoA/Rho kinase system in pulmonary hypertension |
| Q90432956 | Longitudinal Evaluation of Pulmonary Arterial Hypertension in a Rhesus Macaque (Macaca mulatta) Model of HIV Infection |
| Q34732817 | Lung involvement in systemic sclerosis |
| Q35872526 | Macrophage migration inhibitory factor mediates hypoxia-induced pulmonary hypertension |
| Q90745453 | Medicinal Plants and Phytochemicals for the Treatment of Pulmonary Hypertension |
| Q36977330 | Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions |
| Q92366655 | MicroRNA‑15a‑5p induces pulmonary artery smooth muscle cell apoptosis in a pulmonary arterial hypertension model via the VEGF/p38/MMP‑2 signaling pathway |
| Q42056008 | Mitochondria-targeted drugs enhance Nlrp3 inflammasome-dependent IL-1β secretion in association with alterations in cellular redox and energy status |
| Q47726007 | Mitochondrial dysfunction and pulmonary hypertension: Cause, Effect or Both. |
| Q84669567 | Monocrotaline-induced pulmonary arterial hypertension is attenuated by TNF-α antagonists via the suppression of TNF-α expression and NF-κB pathway in rats |
| Q59352387 | Monocyte and Alveolar Macrophage Skewing Is Associated with the Development of Pulmonary Arterial Hypertension in a Primate Model of HIV Infection |
| Q55254142 | Mycophenolate Mofetil in a Lupus Patient with Pulmonary Hypertension. |
| Q33786092 | N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats |
| Q91715390 | Nardochinoid B Inhibited the Activation of RAW264.7 Macrophages Stimulated by Lipopolysaccharide through Activating the Nrf2/HO-1 Pathway |
| Q37724192 | New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation |
| Q37669139 | Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension |
| Q60188546 | Nouvelles approches immunopathologiques de l’hypertension artérielle pulmonaire |
| Q34061821 | Novel mechanisms of sildenafil in pulmonary hypertension involving cytokines/chemokines, MAP kinases and Akt. |
| Q37215728 | Nuclear factor κ-B is activated in the pulmonary vessels of patients with end-stage idiopathic pulmonary arterial hypertension. |
| Q51640257 | Occlusive lung arterial lesions in endothelial-targeted, fas-induced apoptosis transgenic mice. |
| Q30600509 | Oral delivery of Angiotensin-converting enzyme 2 and Angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension. |
| Q34068197 | Oxidative stress is associated with increased pulmonary artery systolic pressure in humans. |
| Q41181596 | Oxidative-stress biomarkers in patients with pulmonary hypertension. |
| Q35235680 | Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner |
| Q56388717 | Pathology of pulmonary hypertension |
| Q43885881 | Pathophysiological roles of nuclear factor kappaB (NF-kB) in pulmonary arterial hypertension: effects of synthetic selective NF-kB inhibitor IMD-0354. |
| Q37879213 | Pediatric pulmonary arterial hypertension: current and emerging therapeutic options |
| Q35070520 | Peptide-directed highly selective targeting of pulmonary arterial hypertension |
| Q36487400 | Peripheral blood B lymphocytes derived from patients with idiopathic pulmonary arterial hypertension express a different RNA pattern compared with healthy controls: a cross sectional study |
| Q36499886 | Peripheral blood gene expression profiling for cardiovascular disease assessment |
| Q34084566 | Persistence of complex vascular lesions despite prolonged prostacyclin therapy of pulmonary arterial hypertension |
| Q35573944 | Pharmacogenomics in pulmonary arterial hypertension: Toward a mechanistic, target-based approach to therapy |
| Q46411179 | Physiopathology of pulmonary arterial hypertension. Cellular and molecular aspects |
| Q38051350 | Platelets in pulmonary hypertension: a causative role or a simple association? |
| Q37189115 | Plexogenic arteriopathy in broiler lungs: Evaluation of line, age, and sex influences |
| Q45869636 | Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension |
| Q43175522 | Progressive endothelial cell damage in an inflammatory model of pulmonary hypertension |
| Q34961901 | Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review |
| Q37438481 | Prostacyclin inhibits IFN-gamma-stimulated cytokine expression by reduced recruitment of CBP/p300 to STAT1 in a SOCS-1-independent manner |
| Q37596479 | Protective role of IL-6 in vascular remodeling in Schistosoma pulmonary hypertension |
| Q59303969 | Pulmonary arterial hypertension |
| Q45998745 | Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report. |
| Q53102154 | Pulmonary arterial hypertension in SLE: what do we know? |
| Q38155079 | Pulmonary arterial hypertension: challenges in translational research and a vision for change |
| Q36502869 | Pulmonary arterial remodeling induced by a Th2 immune response |
| Q35804084 | Pulmonary artery enlargement in schistosomiasis associated pulmonary arterial hypertension |
| Q33899409 | Pulmonary hypertension associated with HIV infection: pulmonary vascular disease: the global perspective |
| Q34392802 | Pulmonary hypertension associated with lung transplantation obliterative bronchiolitis and vascular remodeling of the allograft |
| Q38081180 | Pulmonary hypertension in dialysis patients |
| Q33157071 | Pulmonary hypertension: diagnosis and management |
| Q49041508 | Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension |
| Q37773387 | Pulmonary vascular disease associated with parasitic infection--the role of schistosomiasis |
| Q37816401 | Pulmonary vascular disease associated with schistosomiasis |
| Q39057104 | Pulmonary vascular remodeling in pulmonary hypertension |
| Q37867672 | Pulmonary veno-occlusive disease: advances in clinical management and treatments |
| Q36739370 | Pyrrolidine dithiocarbamate restores endothelial cell membrane integrity and attenuates monocrotaline-induced pulmonary artery hypertension |
| Q39291200 | Recent progress in treatment of pulmonary arterial hypertension due to congenital heart disease. |
| Q37139562 | Reduced force of diaphragm muscle fibers in patients with chronic thromboembolic pulmonary hypertension. |
| Q38870144 | Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension. |
| Q37673917 | Relevant issues in the pathology and pathobiology of pulmonary hypertension |
| Q35665448 | Repeated exposure to Aspergillus fumigatus conidia results in CD4+ T cell-dependent and -independent pulmonary arterial remodeling in a mixed Th1/Th2/Th17 microenvironment that requires interleukin-4 (IL-4) and IL-10. |
| Q37802034 | Respiratory involvement in systemic lupus erythematosus |
| Q35725571 | Role of macrophage migration inhibitory factor in the proliferation of smooth muscle cell in pulmonary hypertension |
| Q91792991 | SGK1 Mediates Hypoxic Pulmonary Hypertension through Promoting Macrophage Infiltration and Activation |
| Q38140894 | STAT3 signaling in pulmonary arterial hypertension |
| Q64098812 | Schistosome infection and its effect on pulmonary circulation |
| Q37762646 | Schistosomiasis-associated pulmonary hypertension: pulmonary vascular disease: the global perspective |
| Q34087045 | Schistosomiasis-induced experimental pulmonary hypertension: role of interleukin-13 signaling |
| Q56977976 | Scleroderma Lung Disease |
| Q41079973 | Serum Cytokines in Young Pediatric Patients with Congenital Cardiac Shunts and Altered Pulmonary Hemodynamics. |
| Q33764990 | Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization |
| Q36108039 | Severe pulmonary hypertension: The role of metabolic and endocrine disorders |
| Q33568826 | Sex differences in the pulmonary circulation: implications for pulmonary hypertension |
| Q37133785 | Signal transduction in the development of pulmonary arterial hypertension |
| Q41875321 | Significant intrapulmonary Schistosoma egg antigens are not present in schistosomiasis-associated pulmonary hypertension |
| Q36568847 | Sildenafil Reduces Inflammation and Prevents Pulmonary Arterial Remodeling of the Monocrotaline - induced Disease in the Wistar Rats. |
| Q44705865 | Sildenafil for pulmonary arterial hypertension: still waiting for evidence |
| Q89578350 | Skeletal and Respiratory Muscle Dysfunctions in Pulmonary Arterial Hypertension |
| Q34611424 | Skeletal muscle abnormalities in pulmonary arterial hypertension. |
| Q43014041 | Smurf1 ubiquitin ligase causes downregulation of BMP receptors and is induced in monocrotaline and hypoxia models of pulmonary arterial hypertension |
| Q92287309 | Statin treatment prevents the development of pulmonary arterial hypertension in a nonhuman primate model of HIV-associated PAH |
| Q29346986 | Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment |
| Q40165051 | Systemic arterial endothelial function in children and young adults with idiopathic pulmonary arterial hypertension: is there a relation to pulmonary endothelium-dependent relaxation? |
| Q43277234 | Systemic corticosteroids as first-line treatment in pulmonary hypertension associated with POEMS syndrome |
| Q33679052 | T lymphocyte subset abnormalities in the blood and lung in pulmonary arterial hypertension |
| Q42145272 | Targeting the adventitial microenvironment in pulmonary hypertension: A potential approach to therapy that considers epigenetic change |
| Q97067101 | The Importance of Mechanical Forces for in vitro Endothelial Cell Biology |
| Q41636614 | The Roles of Hypoxia Signaling in the Pathogenesis of Cardiovascular Diseases |
| Q38112032 | The adventitia: Essential role in pulmonary vascular remodeling |
| Q27000503 | The adventitia: essential regulator of vascular wall structure and function |
| Q34268946 | The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension |
| Q39294892 | The combination of exercise and respiratory training improves respiratory muscle function in pulmonary hypertension. |
| Q38077796 | The emergence of new therapeutic targets in pulmonary arterial hypertension: from now to the near future |
| Q39353707 | The first Keystone Symposia Conference on pulmonary vascular isease and right ventricular dysfunction: Current concepts and future therapies |
| Q53316545 | The novel combination of theophylline and bambuterol as a potential treatment of hypoxemia in humans. |
| Q28567772 | The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted |
| Q36117547 | The respiratory system in connective tissue disorders |
| Q36644859 | The right ventricle: biologic insights and response to disease: updated |
| Q37851851 | The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension. |
| Q38104321 | The transforming growth factor-β-bone morphogenetic protein type signalling pathway in pulmonary vascular homeostasis and disease |
| Q37364799 | Therapies for scleroderma-related pulmonary arterial hypertension |
| Q55000062 | Tissue-specific Role of CX3CR1 Expressing Immune Cells and Their Relationships with Human Disease. |
| Q35038418 | Transfer of human hepatocyte growth factor reduces inflammation and prevents pulmonary arterial remodeling in monocrotaline-induced |
| Q41849231 | Transforming growth factor-β signaling promotes pulmonary hypertension caused by Schistosoma mansoni |
| Q33970205 | Up-regulated lipocalin-2 in pulmonary hypertension involving in pulmonary artery SMC resistance to apoptosis |
| Q37100702 | Update in pulmonary arterial hypertension 2007. |
| Q25255715 | Upregulated genes in sporadic, idiopathic pulmonary arterial hypertension |
| Q35533520 | VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension |
| Q35119607 | Varicella zoster virus vasculopathy: analysis of virus-infected arteries |
| Q40706456 | Whipple's disease-associated pulmonary hypertension with positive vasodilator response despite severe hemodynamic derangements |
| Q81522982 | [Biomarkers as prognostic factors in pulmonary arterial hypertension. Rationale and study design] |
| Q84393114 | [Etiopathogenesis and physiopathology in chronic thromboembolic pulmonary hypertension] |
| Q46809537 | [Pulmonary arterial hypertension]. |
| Q83079608 | [Respiratory involvement in systemic lupus erythematosus] |
Search more.